AEGLEA BIOTHERAPEUTICS INC's ticker is AGLE and the CUSIP is 00773J103. A total of 85 filers reported holding AEGLEA BIOTHERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Links
Filings
- All filings
- Annual reports (10-K)
- Quarterly reports (10-Q)
- Insider transactions
- Shareholder votes
- Significant ownership
- Events
EDGAR links
External links
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $1,489 | -62.4% | 3,306 | -75.8% | 0.00% | – |
| Q1 2023 | $3,961 | -89.1% | 13,656 | -83.0% | 0.00% | – |
| Q4 2022 | $36,199 | -58.9% | 80,461 | -52.2% | 0.00% | – |
| Q3 2022 | $88,000 | -40.5% | 168,258 | -42.7% | 0.00% | – |
| Q2 2022 | $148,000 | -64.6% | 293,834 | +61.7% | 0.00% | – |
| Q1 2022 | $418,000 | -55.2% | 181,701 | -7.4% | 0.00% | – |
| Q4 2021 | $932,000 | -39.6% | 196,218 | +1.0% | 0.00% | – |
| Q3 2021 | $1,544,000 | +13.4% | 194,225 | -0.7% | 0.00% | – |
| Q2 2021 | $1,362,000 | +54.8% | 195,535 | +76.0% | 0.00% | – |
| Q1 2021 | $880,000 | -12.7% | 111,090 | -13.3% | 0.00% | – |
| Q4 2020 | $1,008,000 | +304.8% | 128,090 | +265.0% | 0.00% | – |
| Q3 2020 | $249,000 | +6.0% | 35,091 | +37.8% | 0.00% | – |
| Q2 2020 | $235,000 | +1368.8% | 25,467 | +636.7% | 0.00% | – |
| Q1 2020 | $16,000 | -94.2% | 3,457 | -90.4% | 0.00% | – |
| Q4 2019 | $276,000 | +338.1% | 36,127 | +344.8% | 0.00% | – |
| Q3 2019 | $63,000 | -81.3% | 8,122 | -83.5% | 0.00% | – |
| Q2 2019 | $337,000 | +374.6% | 49,319 | +460.2% | 0.00% | – |
| Q1 2019 | $71,000 | -64.9% | 8,804 | -67.4% | 0.00% | – |
| Q4 2018 | $202,000 | -29.1% | 26,983 | -9.5% | 0.00% | – |
| Q3 2018 | $285,000 | -33.3% | 29,818 | -26.0% | 0.00% | – |
| Q2 2018 | $427,000 | +484.9% | 40,308 | +442.9% | 0.00% | – |
| Q1 2018 | $73,000 | +356.2% | 7,424 | +144.9% | 0.00% | – |
| Q4 2017 | $16,000 | +6.7% | 3,032 | 0.0% | 0.00% | – |
| Q3 2017 | $15,000 | +36.4% | 3,032 | +9.7% | 0.00% | – |
| Q2 2017 | $11,000 | -72.5% | 2,765 | -49.4% | 0.00% | – |
| Q1 2017 | $40,000 | +66.7% | 5,464 | 0.0% | 0.00% | – |
| Q4 2016 | $24,000 | -4.0% | 5,464 | +44.2% | 0.00% | – |
| Q3 2016 | $25,000 | – | 3,790 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Yu Fan | 112,044 | $258,000 | 3.49% |
| Aisling Capital Management LP | 1,691,151 | $3,890,000 | 2.10% |
| Sio Capital Management, LLC | 871,101 | $2,004,000 | 0.66% |
| Bain Capital Life Sciences Investors, LLC | 2,847,689 | $6,550,000 | 0.64% |
| Samsara BioCapital, LLC | 883,720 | $2,033,000 | 0.51% |
| Ghost Tree Capital, LLC | 686,599 | $1,579,000 | 0.34% |
| Nantahala Capital Management | 3,200,593 | $7,361,000 | 0.33% |
| UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGMENT CO | 245,678 | $565,000 | 0.29% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 4,059,894 | $9,338,000 | 0.28% |
| Lion Point Capital, LP | 300,000 | $690,000 | 0.16% |